Document is current
Any future updates will be listed below
-
Authors
Samur, Mehmet Kemal https://orcid.org/0000-0002-9978-5682
Fulciniti, Mariateresa https://orcid.org/0000-0002-1432-9742
Aktas Samur, Anil https://orcid.org/0000-0002-0183-0562
Bazarbachi, Abdul Hamid https://orcid.org/0000-0003-0243-4040
Tai, Yu-Tzu https://orcid.org/0000-0001-6199-3569
Prabhala, Rao
Alonso, Alejandro
Sperling, Adam S.
Campbell, Timothy
Petrocca, Fabio
Hege, Kristen
Kaiser, Shari
Loiseau, Hervé Avet
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
Munshi, Nikhil C. https://orcid.org/0000-0002-7344-9795
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA155258, P50 CA100707)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Veterans Affairs (5I01BX001584)
Celgene Corporation and Paula and Roger Riney Foundation.
- License Information
-
More Information
Article History
Received: 16 October 2020
Accepted: 14 January 2021
First Online: 8 February 2021
Competing interests
: K.C.A. has received consulting fees from Bristol-Myers Squibb, Celgene, Gilead, Janssen, Precision Biosciences, Sanofi-Aventis, Takeda, and Tolero, and on the board of directors and stock options Oncopep. N.C.M. is a consultant for BMS, Janssen, Oncopep, Amgen, Karyopharm, Legened, Abbvie, Takeda, and GSK, and on the board of directors and stock options Oncopep. T.C., K.H., and S.K. are employed by Bristol-Myers Squibb. F.P. is employed by Bluebird Bio. Other authors declare no competing interests.
